Sakata J, Kobayashi T, Ohashi T, Hirose Y, Takano K, Takizawa K, Miura K, Ishikawa H, Toge K, Yuza K, Soma D, Ando T, Wakai T
Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan.
Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan.
Eur J Surg Oncol. 2017 Apr;43(4):780-787. doi: 10.1016/j.ejso.2017.01.001. Epub 2017 Jan 19.
This study sought to evaluate the prognostic heterogeneity of Stage III (Union for International Cancer Control, seventh edition) gallbladder carcinoma.
Of 175 patients enrolled with gallbladder carcinoma who underwent radical resection, 22 were classified with Stage IIIA disease (T3N0M0) and 46 with Stage IIIB disease (T2N1M0 [n = 23] and T3N1M0 [n = 23]). The median number of retrieved lymph nodes per patient was 18.
This staging system failed to stratify outcomes between Stages IIIA and IIIB; survival after resection was better for patients with Stage IIIB disease than for patients with Stage IIIA disease, with 5-year survival of 54.9% and 41.0%, respectively (p = 0.366). Multivariate analysis for patients with Stage III disease revealed independently better survival for patients with T2N1M0 than for patients with T3N0M0 (p = 0.016) or T3N1M0 (p = 0.001), with 5-year survival of 77.0%, 41.0%, and 31.0%, respectively. When N1 status was subdivided according to the number of positive nodes, 5-year survival in patients with T2M0 with 1-2 positive nodes, T2M0 with ≥3 positive nodes, T3M0 with 1-2 positive nodes, and T3M0 with ≥3 positive nodes was 83.3%, 50.0%, 45.8%, and 0%, respectively (p < 0.001).
The prognosis of T2N1M0 disease was better than that of T3N0/1M0 disease, suggesting that not all node-positive patients will have uniformly poor outcomes after resection of gallbladder carcinoma. T2M0 with 1-2 positive nodes leads to a favorable outcome after resection, whereas T3M0 with ≥3 positive nodes indicates a dismal prognosis.
本研究旨在评估Ⅲ期(国际癌症控制联盟第七版)胆囊癌的预后异质性。
在175例行根治性切除的胆囊癌患者中,22例被分类为ⅢA期疾病(T3N0M0),46例为ⅢB期疾病(T2N1M0[n = 23]和T3N1M0[n = 23])。每位患者切除的淋巴结中位数为18个。
该分期系统未能区分ⅢA期和ⅢB期的预后;ⅢB期疾病患者切除后的生存率优于ⅢA期疾病患者,5年生存率分别为54.9%和41.0%(p = 0.366)。对Ⅲ期疾病患者的多因素分析显示,T2N1M0患者的生存率独立于T3N0M0患者(p = 0.016)或T3N1M0患者(p = 0.001),5年生存率分别为77.0%、41.0%和31.0%。当根据阳性淋巴结数量对N1状态进行细分时,T2M0伴1 - 2个阳性淋巴结、T2M0伴≥3个阳性淋巴结、T3M0伴1 - 2个阳性淋巴结和T3M0伴≥3个阳性淋巴结患者的5年生存率分别为83.3%、50.0%、45.8%和0%(p < 0.001)。
T2N1M0疾病的预后优于T3N0/1M0疾病,这表明并非所有淋巴结阳性患者在胆囊癌切除术后的预后都同样差。T2M0伴1 - 2个阳性淋巴结切除后预后良好,而T3M0伴≥3个阳性淋巴结则提示预后不佳。